3 citations
,
June 2023 in “Frontiers in Medicine” A new model uses specific blood markers to predict if children's hair loss will return.
3 citations
,
February 2023 in “Frontiers in Immunology” The IGRA test effectively detects past SARS-CoV-2 exposure, especially using nucleocapsid peptides.
3 citations
,
November 2022 in “European Journal of Human Genetics” New models predict male pattern baldness better than old ones but still need improvement.
2 citations
,
May 2025 in “Diagnostics” ATR-FTIR spectroscopy could help monitor alopecia areata treatment response non-invasively.
2 citations
,
March 2025 in “PNAS Nexus” Raman spectroscopy can detect radiation exposure in mouse hair with high accuracy for up to 7 days.
2 citations
,
January 2024 in “IEEE Access” AlopeciaDet accurately detects Alopecia Areata early using advanced image analysis.
2 citations
,
October 2023 in “Cancer Reports” Mitochondrial features can predict colorectal cancer outcomes and improve immunotherapy.
2 citations
,
January 2022 in “Clinical, Cosmetic and Investigational Dermatology” The refined wash test is a reliable way to measure daily hair loss and can tell the difference between different types of hair loss.
1 citations
,
July 2025 in “Middle East Fertility Society Journal” Autoimmune markers may help diagnose and manage PCOS.
1 citations
,
June 2025 in “Frontiers in Genetics” Key genes IRF2BP2 and EGFR are linked to Hetian sheep's double-coat fleece.
1 citations
,
February 2025 in “Journal of the Neurological Sciences” Beta-trace protein may help diagnose and predict treatment response in certain nerve disorders.
1 citations
,
August 2023 in “Diagnostics” Women with PCOS are more likely to develop kidney stones, especially those with certain PCOS types.
1 citations
,
August 2023 in “Clinical Cosmetic and Investigational Dermatology” Exclamation mark hairs help distinguish syphilitic alopecia from alopecia areata.
1 citations
,
June 2023 in “Nutrients” Vitamin D deficiency is linked to a higher chance of metabolic syndrome in women with PCOS.
1 citations
,
February 2023 in “Pharmaceutics” Cell proteomic footprinting enhances cancer vaccine quality by ensuring correct antigen composition.
1 citations
,
December 2022 in “Clinical, Cosmetic and Investigational Dermatology” Midscalp hair density and terminal hair percentage are good indicators of female pattern hair loss severity.
1 citations
,
August 2021 in “International Journal of General Medicine” Severe and early hair loss may indicate a higher risk of heart disease.
1 citations
,
January 2017 in “Journal of rare disease research & treatment” Obesity is common in PCOS patients and early treatment is important for their heart and metabolic health.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Higher oxidative stress markers are linked to hair loss in post-COVID-19 patients.
A high neutrophil-to-lymphocyte ratio may predict poor response to hair loss treatment.
February 2026 in “Pharmaceuticals” KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.
February 2026 in “iScience” Hair metal analysis may help diagnose Parkinson's disease and suggests gut involvement.
January 2026 in “Aging and Disease” DKK proteins could help diagnose and treat various non-cancerous diseases.
The model predicts minoxidil's effectiveness and side effects better than traditional methods.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2025 in “Clinical and Translational Medicine” DNAJB9 cfRNA could help diagnose and treat female hair loss.
October 2025 in “Medical Journal of Babylon” Higher testosterone and lower Vitamin D levels are linked to hair loss in female COVID-19 patients.
September 2025 in “PeerJ” FCER1A and RGS1 may help diagnose and treat systemic lupus erythematosus.
September 2025 in “The Open Dermatology Journal” The AI showed high accuracy in diagnosing skin conditions but needs improvement for immunological and infectious disorders.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.